Your browser doesn't support javascript.
loading
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.
Cornell, Robert F; Fraser, Raphael; Costa, Luciano; Goodman, Stacey; Estrada-Merly, Noel; Lee, Cindy; Hildebrandt, Gerhard; Gergis, Usama; Farhadfar, Nosha; Freytes, César O; Kamble, Rammurti T; Krem, Maxwell; Kyle, Robert A; Lazarus, Hillard M; Marks, David I; Meehan, Kenneth; Patel, Sagar S; Ramanathan, Muthalagu; Olsson, Richard F; Wagner, John L; Kumar, Shaji; Qazilbash, Muzaffar H; Shah, Ninah; Hari, Parameswaran; D'Souza, Anita.
Afiliação
  • Cornell RF; AbbVie, North Chicago, Illinois.
  • Fraser R; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Costa L; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
  • Goodman S; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Estrada-Merly N; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Lee C; Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Hildebrandt G; Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
  • Gergis U; Department of Medical Oncology, Division of Hematological Malignancies, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Farhadfar N; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL.
  • Freytes CO; Texas Transplant Institute, San Antonio, Texas.
  • Kamble RT; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
  • Krem M; Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
  • Kyle RA; Mayo Clinic Rochester, Rochester, Minnesota.
  • Lazarus HM; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
  • Marks DI; Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
  • Meehan K; Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
  • Patel SS; Blood and Marrow Transplant Program, University of Utah, Salt Lake City, Utah.
  • Ramanathan M; Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts.
  • Olsson RF; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
  • Wagner JL; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Kumar S; Mayo Clinic Rochester, Rochester, Minnesota.
  • Qazilbash MH; MD Anderson Cancer Center, Houston, Texas.
  • Shah N; Division of Hematology-Oncology, University of California San Francisco, San Francisco, California.
  • Hari P; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • D'Souza A; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: andsouza@mcw.edu.
Transplant Cell Ther ; 27(3): 264.e1-264.e7, 2021 03.
Article em En | MEDLINE | ID: mdl-33781533
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Amiloidose Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Amiloidose Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2021 Tipo de documento: Article